BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

November 02, 2026 | Regulatory

InventisBio’s Nomelcitinib Achieves Both Primary and Key Secondary Endpoints in Phase III Psoriasis Trial

InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key seconda...

November 03, 2026 | News

Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Gro...

November 03, 2026 | News

Zhimeng Biopharma Completes Enrolment of 255 Patients in Pivotal ALS Phase II/III Trial in China

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154,...

November 03, 2026 | News

Nuance Pharma Doses First Patient in China Phase III Trial of Actair for House Dust Mite Allergy

Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of ho...

November 03, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

October 30, 2026 | News

Kelun-Biotech Secures China NMPA Review for Sac-TMT and Pembrolizumab Combination in First-Line Lung Cancer

This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen o...

October 29, 2026 | News

Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

October 29, 2026 | News

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

October 28, 2026 | Analysis

TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours

TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading pro...

October 28, 2026 | News

Innovent Seeks China Approval for Sintilimab and Nolgileucel Combination in Advanced Melanoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

October 28, 2026 | News

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

October 27, 2026 | Analysis

HanchorBio and Aston Sci Join Forces to Advance Dual-Action Cancer Immunotherapy Targeting Solid Tumours

Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...

October 27, 2026 | News

Tairex Unveils AI-Powered Agent Hospital Ecosystem to Transform Multidisciplinary Clinical Decision-Making

Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, unveiled the Multidisciplinar...

October 27, 2026 | News

Stay Connected